To investigate the association between amino acid metabolic reprogramming and intervertebral disc degeneration (IDD), highlighting its potential implications for treatment.
Key Findings:
Identified 43 genes associated with altered amino acid metabolism, which may play critical roles in IDD progression.
Selected five pivotal genes: CETP, AIFM1, GM2A (up-regulated); PNPLA2, AGK (down-regulated), with potential implications for targeted therapies.
Nomogram prediction model achieved an AUC value of 0.812, indicating strong predictive capability.
Degenerated discs showed increased immune infiltration and compromised protective mechanisms, suggesting a link to disease severity.
Interpretation:
The identified five-gene core signature is significantly linked to IDD and may represent a crucial regulatory pathway for diagnosis and therapy, warranting further investigation into its clinical utility.
Limitations:
Study relies on publicly available datasets, which may have inherent biases, such as sample size and demographic variability.
Further validation in clinical settings is necessary to confirm findings and assess their generalizability.
Conclusion:
The study highlights the potential of amino acid metabolism-related genes as biomarkers and therapeutic targets in IDD.
